Trials
3 active
5 in total · 1 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Anlotinib (AL3818) 12 mg orally administered once daily in 21-day cycles (14 days on treatment, 7 days off treatment)”In the company’s words, NCT03016819 on ClinicalTrials.gov
- Tested for
- Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma, Soft-Tissue Sarcoma, Endometrial Neoplasms, Ovarian Neoplasms, Soft Tissue Sarcoma (STS), Glioblastoma
- Main trialPhase 3
- “THIS STUDY IS CURRENTLY RECRUITING PATIENTS WITH ALVEOLAR SOFT PART SARCOMA ONLY AND IS NO LONGER RECRUITING PATIENTS WITH SYNOVIAL SARCOMA OR LEIOMYOSARCOMA. This study evaluates the safety and efficacy of AL3818 (anlotinib) hydrochloride in the treatment of metastatic or advanced alveolar soft part sarcoma (ASPS), leiomyosarcoma (LMS), and synovial sarcoma (SS). All participants with ASPS will receive open-label AL3818. In participants with LMS or SS, AL3818 will be compared to IV dacarbazine. Two-thirds of the participants will receive AL3818, one-third of the participants will receive IV…”In the company’s words, NCT03016819 on ClinicalTrials.gov
- Other names
- Anlotinib Hydrochloride · Anlotinib · Catequentinib · Catequentenib
Other drugs for Alveolar Soft Part Sarcoma
- BenmelstobartChia Tai Tianqing Pharmaceutical Group Co., Ltd. · Phase 2
- FutibatinibTaiho · Phase 1
- PimitespibTaiho · Phase 1
- TAS-102Taiho · Phase 1
- TAS-115Taiho · Phase 1
- ZimberelimabTaiho · Phase 1
Coming up3
- 31 Mar 2027Phase 1 trial completes · ClinicalTrials.gov
- Dec 2027Phase 3 trial completes · ClinicalTrials.gov
- 1 Sep 2030Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials5
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Dec 2027 | Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS) | |
| Phase 1/2Not yet recruiting | 1 Sep 2030 | A Study of Catequentinib Hydrochloride (AL3818) in Endometrial, LGSOC, STS or GBM Cancers | |
| Phase 1Not yet recruiting | 31 Mar 2027 | Catequentinib Hydrochloride (AL3818) Drug-Drug Interaction Study in Healthy Volunteers | |
| Phase 3Unknown | Oct 2024 | Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002) | |
| Phase 3Ended | not given | A Phase 1/2a/3 Evaluation of the Safety and Efficacy of Adding AL3818 (Anlotinib, INN: Catequentinib), a Dual Receptor Tyrosine Kinase Inhibitor, to Standard Platinum-Based Chemotherapy in Subjects with Recurrent or Metastatic Endometrial,Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma. |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026